Allergan Plc (AGN)

164.85
2.40 1.50
NYSE : Health Technology
Prev Close 162.43
Open 163.80
Day Low/High 162.50 / 165.15
52 Wk Low/High 114.27 / 197.00
Volume 8.65M
Avg Volume 2.56M
Exchange NYSE
Shares Outstanding 327.80M
Market Cap 42.47B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (2.23%)

Latest News

Replay: What to Watch in The Markets: AbbVie-Allergan, Micron, Buffett, and More

Replay: What to Watch in The Markets: AbbVie-Allergan, Micron, Buffett, and More

The ActionAlertsPLUS team breaks down what investors need to know on Tueday, including: AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.

Getting Nervous

After days of complacency, we see a shift in sentiment and folks are getting the jitters.

5 Blockbuster M&A Deals of 2019

5 Blockbuster M&A Deals of 2019

AbbVie takes over Allergan. But, it's not the biggest deal of 2019...

Dow Ends Lower, Stocks Fall as Powell Says Fed 'Grappling' with Rate Cut

Dow Ends Lower, Stocks Fall as Powell Says Fed 'Grappling' with Rate Cut

Major indexes declined Tuesday after Federal Reserve Chairman Jerome Powell hedged on a possible rate cut.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

AbbVie Buys Allergan for $63 Billion: Was the Price Just Right?

AbbVie Buys Allergan for $63 Billion: Was the Price Just Right?

AbbVie to purchase botox maker Allergan in $63 billion deal, but is the price just right?

Allergan Agrees to $63 Billion Takeover From AbbVie in Blockbuster Pharma Deal

Allergan Agrees to $63 Billion Takeover From AbbVie in Blockbuster Pharma Deal

Allergan shares surged the most in more than 25 years Tuesday after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie .

I Believe AbbVie and Allergan Need Each Other

I Believe AbbVie and Allergan Need Each Other

With no other bidder expected to emerge, this is a high risk arbitrage play.

Shares of Botox Maker Allergan Get a Lift

Shares of Botox Maker Allergan Get a Lift

AbbVie is Real Money's Stock of the Day. The biopharmaceutical giant announced a planned $63 billion takeover of Allergan. Action Alerts PLUS Senior Portfolio Analyst Jeff Marks breaks down what investors need to know about the deal.

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

PFE was ready to pay $160 billion until U.S. regulators blocked the deal.

Another Day, Another Deal: What to Watch from AbbVie, Allergan, Micron, Buffett

Another Day, Another Deal: What to Watch from AbbVie, Allergan, Micron, Buffett

Wall Street woke up to another major deal. Here's what to watch from AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement

AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement

Let's look closer at the charts and indicators of ABBV.

Dow Futures Flat, Dollar Sips as Trade Concerns Trim Risk Appetite Ahead of G20

Dow Futures Flat, Dollar Sips as Trade Concerns Trim Risk Appetite Ahead of G20

U.S. equity futures drifted lower Tuesday, setting up the S&P 500 for its first three-day decline since early May, as investors peel back from recent record highs and take a defensive stance on risk ahead of this weekend's G20 Summit in Japan.

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.

Micron, FedEx, Trump-Xi, Tesla and Amazon - 5 Things You Must Know

Micron, FedEx, Trump-Xi, Tesla and Amazon - 5 Things You Must Know

U.S. stock futures decline as investors take a defensive stance on risk ahead of this weekend's G-20 summit in Japan; Micron reports earnings Tuesday; FedEx, which also reports earnings, sues the U.S. government arguing new trade regulations put an 'impossible burden' on the company to monitor its shipments.

Wild Week Ahead

The intermediate-term sentiment indicators don’t show too much giddiness -- yet -- but look at all the market has on its plate this week.

Aegon Announces Purchase Of Shares To Neutralize 2018 Final Stock Dividend

Aegon Announces Purchase Of Shares To Neutralize 2018 Final Stock Dividend

Aegon will repurchase 32,873,805 common shares to neutralize the dilutive effect of the 2018 final stock dividend.

Ironwood And Allergan Report Positive Topline Data From Phase IIIb Trial Of LINZESS® (linaclotide) In Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood And Allergan Report Positive Topline Data From Phase IIIb Trial Of LINZESS® (linaclotide) In Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and  Allergan plc (NYSE:AGN) today announced positive topline data from a Phase IIIb clinical trial evaluating LINZESS (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with IBS-C.

Aegon Bank Successfully Prices Inaugural EUR 500 Million Senior Non-Preferred Notes

Aegon Bank Successfully Prices Inaugural EUR 500 Million Senior Non-Preferred Notes

Today, Aegon Bank priced its inaugural EUR 500 million 5 year Senior Non-Preferred notes with a yield of 0.

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin

Moderna, Six Flags, Chevron and More: 'Mad Money' Lightning Round

Moderna, Six Flags, Chevron and More: 'Mad Money' Lightning Round

A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.

We're in Bizarro Land: Cramer's 'Mad Money' Recap (Wednesday 6/5/19)

We're in Bizarro Land: Cramer's 'Mad Money' Recap (Wednesday 6/5/19)

Investors should consider recession-proof names in the current environment, Jim Cramer says.

Watch These 9 Companies in a Botox Export Boom Out of South Korea

Watch These 9 Companies in a Botox Export Boom Out of South Korea

South Korea is the plastic surgery capital of the world. These companies are manufacturing botox strains - but the big business is abroad, if they can crack the China and U.S. markets.

Bas NieuweWeme Appointed As CEO Of Aegon Asset Management

Bas NieuweWeme Appointed As CEO Of Aegon Asset Management

Aegon today announces that Sarah Russell (1962, Australian), member of Aegon's Management Board and Global CEO of Aegon Asset Management, will step down.

Allergan And Gedeon Richter Receive U.S. FDA Approval For Expanded Use Of VRAYLAR® (cariprazine) In The Treatment Of Bipolar Depression

Allergan And Gedeon Richter Receive U.S. FDA Approval For Expanded Use Of VRAYLAR® (cariprazine) In The Treatment Of Bipolar Depression

- New Indication Makes VRAYLAR First and Only Dopamine and Serotonin Partial Agonist to Treat the Full Spectrum of Bipolar I Symptoms in Manic, Mixed, and Depressive Episodes -

Allergan Announces Updated Presentation Time At The Bernstein Strategic Decisions Conference

Allergan Announces Updated Presentation Time At The Bernstein Strategic Decisions Conference

DUBLIN, May 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 35 th Annual Strategic Decisions Conference in New York, NY.

TheStreet Quant Rating: D+ (Sell)